KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Change in Accured Expenses (2023)

Biocryst Pharmaceuticals (BCRX) has disclosed Change in Accured Expenses for 7 consecutive years, with $1.6 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Change in Accured Expenses changed N/A year-over-year to $1.6 million, compared with a TTM value of $1.2 million through Sep 2023, changed N/A, and an annual FY2021 reading of $4.2 million, down 38.4% over the prior year.
  • Change in Accured Expenses was $1.6 million for Q3 2023 at Biocryst Pharmaceuticals, up from -$2.8 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $1.6 million in Q3 2023 and bottomed at $1.6 million in Q3 2023.